Floatz logo

cc-5013

Leukemia

M.D. Anderson Cancer CenterPhase 2Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
61/ 100
Competitive Position
65/ 100

Competitive context

124 Active assets in the Leukemia cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
Inhye Ahn
Phase 3BB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BB
PEGASPARGASE
Dana-Farber Cancer Institute
Phase 3BB
MERCAPTOPURINE ANHYDROUS
Dana-Farber Cancer Institute
Phase 3BB
FILGRASTIM
Hospital General de Mexico
Phase 4BB

View all 50 →

Same molecule, other indications

cc-5013 is also rated in:

B-cell non-Hodgkin lymphomaDormant
BBB
Indicative ·
75 / 100
View asset →
Recurrent Adult Hodgkin LymphomaDormant
BBB
Indicative ·
74 / 100
View asset →
adult T-cell leukemia/lymphomaDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →